LONDON, Oct 19 (Reuters) - AstraZeneca Plc shares fell more than 3 percent on Friday after the European Patent Office revoked a key patent on its key asthma drug Symbicort. The move puts at risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback